DiFi human colon carcinoma cells are stimulated by the transforming growth factor-a (TGF-a)/epidermal growth factor (EGF) receptor autocrine loop. Exposure of DiFi cells to monoclonal antibody (mAb) 225, which blocks ligand-induced activation of the EGF receptor, induces G1 arrest and subsequent cell death via apoptosis. We investigated the signal pathways by which basic ®bro-blast growth factor (bFGF) and insulin-like growth factor-1 (IGF-1) modulate mAb 225-induced G1 arrest and apoptosis in DiFi cells. Both bFGF and IGF-1 activated the mitogen-activated protein kinase (MAPK) kinase (MEK) pathway in DiFi cells. Additionally, IGF-1 activated the phosphoinositide 3-kinase (PI-3K)/Akt pathway. Both bFGF and IGF-1 inhibited mAb 225-induced apoptosis; however, bFGF provided sustained protection against apoptosis, while the protection by IGF-1 was only temporary. Also, bFGF reversed the mAb 225-induced increase in the p27
Introduction
Our previous studies have shown that the anti-human epidermal growth factor (EGF) receptor monoclonal antibody (mAb) 225 competes with EGF or transforming growth factor-a (TGF-a) for receptor binding, prevents ligand-induced receptor tyrosine kinase activation, and inhibits the proliferation of a variety of cultured and xenografted human cancer cells that are stimulated by the TGF-a/EGF receptor autocrine loop (Fan et al., 1993 (Fan et al., , 1994 Gill et al., 1984; . We demonstrated that in most malignant cell lines examined, mAb 225 inhibited growth primarily by inducing expression of p27 Kip1 and arresting cells in the G1 phase of the cell cycle (Fan et al., 1997; Peng et al., 1996) . In nonmalignant epithelial cells, mAb 225 produced a more prominent cytostatic eect, causing nearly complete arrest of cells in G1 phase (Chou et al., 1999; Stampfer et al., 1993) . It has been postulated that this antibody-induced growth inhibition results from interruption of the TGF-a/EGF receptor autocrine loop in these cells (Baselga et al., 1996; Van de Vijver et al., 1991) . Interestingly, exposure of DiFi colon carcinoma cells to mAb 225 not only arrested the cell cycle in G1 phase (with a concomitant increase in the level of p27 Kip1 and a decrease in CDK2 activity) but also induced subsequent cell death (Wu et al., , 1996 .
The DiFi human colorectal cancer cell line was derived from a patient with familial adenomatous polyposis with extracolonic features characteristic of the Gardner syndrome (Gross et al., 1991; Olive et al., 1993; . Our laboratory is interested in studying the underlying mechanism by which mAb 225 induces apoptosis in DiFi cells. We recently have shown that apoptosis can be induced by several dierent anti-EGF receptor mAbs, each of which binds to dierent epitopes of the EGF receptor in DiFi cells (Liu et al., 2000) . This observation makes it unlikely that mAb 225 induces apoptosis by crossreacting with an unidenti®ed`death' protein on DiFi cell surface. The apoptosis was characterized by activation of the initiation caspase-8 pathway, which was detected between 8 and 16 h after exposure of the cells to the antibody. The initiation caspase-9 was also activated a few hours after the activation of caspase-8. Activation of the initiation caspases triggered the activation of the execution caspase-3 and cleavage of poly(ADP)-ribosepolymerase (PARP), a well-characterized caspase-3 substrate. Pre-exposure of the cells to the caspase-3-speci®c inhibitor DEVD-CHO partially reduced the mAb 225-induced PARP cleavage and apoptosis, whereas pre-exposure of the cells to the pancaspase inhibitor z-VAD-fmk completely inhibited mAb 225-induced apoptosis. Caspases-3, -8 and -9 were not activated in those cell lines in which mAb 225 induced only cell cycle arrest in G1 phase. In contrast to the apoptosis of DiFi cells induced by ultraviolet irradiation, which strongly activated the c-jun Nterminal kinase-1 (JNK1) and the caspase cascade, mAb 225-induced apoptosis and activation of the caspase cascade in DiFi cells were not associated with activation of JNK1 (Liu et al., 2000) .
DiFi cells are stimulated by the TGF-a/EGF receptor autocrine loop (Gross et al., 1991; and thus can grow in low-serum medium in cell culture. We found that the antibody-induced apoptosis was more prominent when DiFi cells were cultured in low-serum medium. When the cells were cultured in high-serum medium, apoptosis could still be induced by mAb 225 but to a lesser extent (approximately 50% less), suggesting that some serum factors might play important roles in modulating mAb 225-induced apoptosis in these cells.
Serum contains many growth factors, such as EGF, PDGF, bFGF, and IGF-1, whose biological eects are mediated by a family of high-anity receptors with tyrosine kinase activity (Ullrich and Schlessinger, 1990) . The binding of these growth factors to their individual cognate receptors triggers a cascade of biochemical signal transduction that eventually leads to cell growth and dierentiation in many cell types. One type of cells is often stimulated by an orchestra of multiple growth factors, and dierent growth factors may activate identical or overlapping signal pathways in one type of cell but trigger dierential signals in others.
In the current study, we investigated how bFGF and IGF-1 modulate mAb 225-induced G1 arrest and apoptosis in DiFi cells. We found that bFGF could strongly inhibit both the antibody-induced cell cycle arrest in G1 phase and the subsequent apoptosis. In contrast, although IGF-1 delayed the onset of apoptosis, it did not prevent mAb 225-induced G1 cell cycle arrest. A human-mouse chimeric version of mAb 225 (C225) is currently being evaluated in clinical trials for its antitumor activity against human cancers. Study of the mechanism by which mAb 225 induces apoptosis in DiFi cells may direct us to identify new target(s) to maximize the antitumor eect of mAb 225 by inducing apoptosis in a variety of cancer cells. The results of these studies shed new light on the mechanism by which mAb 225 induces G1 arrest and apoptosis in DiFi cells.
Results

Modulation of mAb 225-induced apoptosis by growth factors
We have previously shown that the addition of insulin could delay the onset but not prevent the occurrence of mAb 225-induced apoptosis . In the current study, we further examined the eects of several growth factors, each of which will activate the corresponding cell membrane receptors with tyrosine kinase activities, on mAb 225-mediated DiFi cell death. When stained with Hoechst 33342, a¯uorescent dye that stains the DNA in living cells, approximately 25% of DiFi cells showed chromosome condensation and fragmentation under a¯uorescent microscope 24 h after mAb 225 treatment. This typical apoptotic change was remarkably reduced when bFGF, IGF-1, or EGF was added to the culture medium (Figure 1) . PDGF, in contrast, did not signi®cantly protect DiFi cells from mAb 225-induced chromosome condensation and fragmentation (data not shown).
Because mAb 225-induced apoptosis is characterized by enzymatic activation of caspase-8, caspase-9, and subsequently caspase-3 (Liu et al., 2000) , we next examined the eects of bFGF and IGF-1 on the activities of these caspases. The antibody-induced activation of these three caspases was signi®cantly reduced by bFGF or IGF-1 (Figure 2 ). This inhibition (Figure 3a ). In contrast, although IGF-1 inhibited mAb 225-induced chromosome condensation and activation of the caspases, it failed to protect DiFi cells from apoptosis following extended exposure to mAb 225 ( Figure 3b ). It is interesting to note that, while bFGF reached a plateau of maximal antiapoptotic eect at very low concentrations, the inhibition of mAb 225-induced apoptosis by IGF-1 was only minimally dose-dependent. EGF, on the other hand, produced a biphasic eect on mAb 225-induced cell death (Figure 3c ). It is known that EGF at very Figure 2 Activation of caspases-8, -9 and -3 by mAb 225 and its inhibition by bFGF and IGF-1. DiFi cells were cultured in medium containing 0.5% FBS with either mAb 225 alone or the combination of 5 nM mAb 225 with 5 nM bFGF or IGF-1 for 8 and 24 h. Cell lysates were prepared and subjected to enzymatic assays for the activities of caspase-8 (a), caspase-9 (b), and caspase-3 (c) as described in the text Oncogene bFGF and IGF-1 modulate anti-EGFR mAb-induced apoptosis and G1 arrest B Liu et al low concentrations stimulates DiFi cell proliferation but paradoxically inhibits DiFi cell growth at concentrations higher than receptor-saturating concentrations (41 nM) . Because mAb 225 competes with EGF for receptor binding with a similar Kd (Gill et al., 1984; Sato et al., 1983) , titration of 5 nM mAb 225 with increasing concentrations of EGF in the culture medium therefore produced a biphasic eect on proliferation: cell proliferation was stimulated when the concentrations of EGF and mAb 225 were at the proper ratio, and the cell proliferation was inhibited when the ratio was either lower or higher.
We used a more sensitive apoptosis-speci®c ELISA to further quantitatively compare the eects of bFGF and IGF-1 on the kinetics of mAb 225-induced apoptosis in DiFi cells. We found that bFGF strongly prevented apoptosis, whereas IGF-1 only delayed the occurrence of mAb 225-induced apoptosis ( Figure 4 ). It is noted that, in contrast to the results shown in Figures 1 and 2 , in which the anti-apoptotic eects of bFGF and IGF-1 on mAb 225-induced apoptosis were similar at the 24-h time point, the more sensitive ELISA assay demonstrated that there was already a quantitative dierence between bFGF and IGF-1 in inhibiting mAb 225-induced apoptosis (Figure 4 ). This is in agreement with our ®ndings indicating that there was a signi®cant dierence in cell number between the cells treated with mAb 225 plus bFGF and the cells treated with mAb 225 plus IGF-1 at 72 h after mAb 225 treatment.
bFGF but not IGF-1 prevents mAb 225-induced G1 arrest by restoring CDK2 activity and promoting cell cycle traversal Apoptotic cells undergoing concurrent DNA degradation are usually found by¯ow cytometric analysis in the pre-G0/G1 phase. Exposure of the DiFi cells to 5 nM mAb 225 for 24 h not only markedly increased the proportion of cells in pre-G0/G1 phase (indicating an occurrence of apoptosis) but also increased the proportion of the cells in G1 phase (from 61.7 to 82.4%) and decreased the proportion of the cells in S phase (from 26.5 to 7.2%) ( Figure 5 ). We found that the addition of 5 nM bFGF to the culture medium signi®cantly reduced the proportion of pre-G0/G1 phase apoptotic cells (proportion of cells reduced from 32.0 to 7.67%) and partially inhibited the G1 arrest (from 82.4 to 74.8%). The presence of 5 nM EGF in the culture medium also prevented the antibodyinduced pre-G0/G1 cell accumulation and G1 phase arrest. However, although IGF-1 reduced the proportion of cells in the pre-G0/G1 phase (from 32.0 to 7.54%), it failed to prevent cell cycle arrest in G1 phase (82.4 versus 81.7% in cells treated with mAb 225 alone or in combination with IGF-1).
We have previously shown that the arrest in G1 by mAb 225 is accompanied by a reduced level of CDK2 activity and a resultant dephosphorylation of Rb protein (Wu et al., 1996) . To further demonstrate the dierential eect of bFGF and IGF-1 in regulating mAb 225-induced G1 arrest, we examined the levels of CDK2 activity following treatment. Treatment of DiFi cells with mAb 225 inhibited both total CDK2 and cyclin E-associated CDK2 activity (Figure 6a,b) . The inhibition of CDK2 activity was partially restored by the presence of bFGF, but not IGF-1, in the culture medium. Western blot analysis with antibodies that recognize both hyperphosphorylated and hypophosphorylated Rb consistently showed that the dephosphorylation of Rb induced by mAb 225 was prevented by the presence of bFGF, but not IGF-1, in the culture medium (Figure 6c ).
Differential mechanism of bFGF and IGF-1 in modulating mAb 225-induced apoptosis
We found that both bFGF and IGF-1 activated the MEK/MAPK pathway, as shown by increased phosphorylation on MAPK (Figure 7a ). In addition, IGF-1, but not bFGF, activated the PI-3K/Akt pathway, as shown by increased phosphorylation on Akt ( Figure  7b ). DiFi cells express detectable levels of MEK/ MAPK and PI-3K/Akt activity produced by TGF-a/ EGF receptor autocrine stimulation. Exposure of the cells to mAb 225 inhibited the autocrine-stimulated MEK/MAPK and PI-3K/Akt activity (Figure 7c,d) . The presence of bFGF, but not IGF-1, in the culture medium partially reversed mAb 225-induced inhibition of MEK/MAPK activity at the 24-h time point. In contrast, the presence of IGF-1, but not bFGF, in the culture medium reversed the mAb 225-induced inhibition of PI-3K/Akt activity in the early hours but did not sustain the reversal of PI-3K activity in extended hours (Figure 7c,d) . Cell lysates were prepared at individual time points and subjected to an apoptosis-speci®c ELISA assay as described in the text. The mAb 225-induced apoptosis is presented as a fold increase over results for untreated cells at an optical absorbance at 405 nm bFGF and IGF-1 modulate anti-EGFR mAb-induced apoptosis and G1 arrest B Liu et al Although IGF-1 was able to activate the MEK/ MAPK pathway, the activation of MAPK by IGF-1 apparently was not sucient to reverse the mAb 225-induced inhibition of MAPK activity and to release the cells from mAb 225-induced cell cycle arrest at G1 phase. Exposure of DiFi cells to mAb 225 for 16 to 24 h resulted in increased expression of p27 Kip1 , which was prevented by co-culture of the cells with bFGF but not with IGF-1 (Figure 8a ). We further examined the eects of bFGF and IGF-1 on mAb 225-induced G1 arrest and CDK2 activity inhibition by selectively blocking the MEK/MAPK pathway with the MEK inhibitor PD98059 and the PI-3K/Akt pathway with the PI-3K inhibitor LY294002. As shown in Figure 8b , treatment of DiFi cells with mAb 225 strongly inhibited CDK2 activity (lane 5), and this inhibition was partially prevented by co-culture of the cells with bFGF (lane 6). This eect of bFGF was blocked by the MEK inhibitor PD98059 (lane 7) but not by the PI-3K inhibitor LY294002 (lane 8). In contrast, IGF-1 failed to prevent mAb 225-induced inhibition of CDK2 activity, and the addition of PD98059 or LY294002 accordingly did not produce any signi®cant eect (Figure 8c) .
We also analysed the eects of bFGF and IGF-1 in modulating the DNA fragmentation induced by mAb 225 ( Figure 9 ). As we have previously reported, mAb 225-induced apoptosis is characterized by an appearance of DNA ladder . Appearance of this mAb 225-induced DNA ladder (lane 4) was prevented by both bFGF (lane 5) and IGF-1 (lane 8). However, the prevention of the mAb 225-induced Figure 5 Arrest of DiFi cells at G1 phase of the cell cycle by mAb 225 and its modulation by bFGF, IGF-1, and EGF. DiFi cells were cultured in medium containing 0.5% FBS with mAb 225 alone or the combination of 5 nM mAb 225 with 5 nM bFGF, IGF-1, or EGF for 24 h. Both adherent and non-adherent cells were harvested. Cell cycle distributions were analysed by¯ow cytometry as described in the text Oncogene bFGF and IGF-1 modulate anti-EGFR mAb-induced apoptosis and G1 arrest B Liu et al DNA ladder by bFGF was blocked by the MEK inhibitor PD98059 (lane 7) but only minimally aected by the PI-3K inhibitor LY294002 (lane 6). In contrast, the prevention of the DNA ladder by IGF-1 was blocked by LY294002 (lane 9) but minimally aected by the PD98059 (lane 10). Taken together, the results shown in Figures 8 and 9 strongly indicate that bFGF rescues DiFi cells from both mAb 225-induced inhibition of CDK2 activity and apoptosis through a PD98059-sensitive pathway. On the other hand, although IGF-1 also stimulated MAPK phosphorylation/activation in DiFi cells, the activation of MAPK apparently was not sucient to restore mAb 225-induced inhibition of CDK2 activity, and accordingly IGF-1 could not reverse the mAb 225-induced G1 arrest. However, IGF-1 was able to delay the cells from committing to mAb 225-induced apoptosis, a process that was LY29400-sensitive, suggesting that this process occurred through the PI-3K/Akt pathway.
Discussion
Growth factors drive quiescent cells into becoming actively cycling and dividing cells. The response of cells to the mitogenic signals produced by growth factors has been described as occurring in two steps (Pledger et al., 1977) . The quiescent cells are ®rst advanced into G1 phase by so-called`competence' factors such as EGF, bFGF, and PDGF. After traversing a portion of the G1 phase of the cell cycle, the cells become committed to DNA synthesis under the in¯uence of progression factors' such as insulin and IGF-1. A successful transition through all of G1 phase requires sustained growth factor stimulation over a period of several hours. If this stimulation ceases, the cells will revert to the G0 phase. When the cells reach a critical point in the cell cycle termed the`restriction point', only the presence of a`progression' factor is needed (Pardee, 1989) . This`restriction point' coincides with the`G1 checkpoint' controlled by the level of phosphorylation of the Rb protein, which is regulated by the activities of CDKs. The latter are activated by cyclins and inhibited by so-called CDK inhibitors such as p27
Kip1 (Sherr, 1996; Sherr and Roberts, 1999) . Growth factor-stimulated activation of the PI-3K pathway plays a vital role in cell survival. Activation of PI-3K increases the levels of phospholipids, including phosphatidylinositol-3,4-bisphosphate (PtdIns-3,4-P 2 ) and PtdIns-3,4,5-P 3 , at the cell membrane (Wymann and Pirola, 1998); and the phospholipids recruit Akt to 
the plasma membrane, where Akt undergoes conformational changes and is activated by phosphorylation at Thr-308/309 and Ser-473/474 by the upstream kinase termed phosphoinositide-dependent kinase (PDK) in a PtdIns-3,4,5-P3-dependent manner (Alessi et al., 1997) . Activated Akt is subsequently released from the membrane to phosphorylate (inactivate) several key apoptosis regulatory molecules, including the proapoptotic bcl-2 family member Bad (Datta et al., 1997; del Peso et al., 1997) , the protease caspase-9 (Cardone et al., 1998) , and the forkhead transcription factor FKHRL1 , and thereby inhibits apoptosis. Recent studies also demonstrated that both the MEK/MAPK pathway and PI-3K/Aktmediated pathway are involved in cell survival. MAPK is a component of a protein kinase cascade linking growth and dierentiation signals with transcription in the nucleus. Activated MAPK (ERK p44/p42) translocates to the nucleus, where it activates transcription by phosphorylation of such transcription factors as Elk-1 and stat3. Several groups (Scheid et al., 1999) have demonstrated a convergence of the Grb2/SOS/Ras/ Raf/MEK/MAPK pathway and the PI-3K/Akt pathway in promoting cell survival Fang et al., 1999) . For example, phosphorylation of Bad at either Ser-136 or Ser-112 will inactivate its proapoptotic function, releasing the pro-survival protein Bcl-x from its constraint by functional Bad (Zha et al., 1996) . While Akt was known to phosphorylate Bad at Ser-136, the MAPK-activated p90 ribosomal S6 kinase family (Rsks) has now been shown to phosphorylate Bad at Ser-112 ). In our current study, we investigated the regulation of mAb 225-induced G1 arrest and apoptosis in DiFi cells by bFGF and IGF-1. Monoclonal antibody 225 speci®cally competes with EGF/TGF-a for EGF receptor binding and blocks ligand-induced receptor downstream signal transduction (Fan et al., 1993 (Fan et al., , 1994 Kawamoto et al., 1983; Sato et al., 1983) . We demonstrated that bFGF inhibited the mAb 225-induced cell cycle arrest at G1 phase in a PD98059-sensitive and LY294002-insensitive pathway, suggesting the involvement of the MEK/MAPK pathway ( Figure  8 ). In contrast, IGF-1 was ineective in inhibiting mAb 225-induced G1 arrest in these cells (Figure 5) , which was consistent with the failure of IGF-1 in reversing mAb 225-induced inhibition of CDK2 activity or prevention of Rb dephosphorylation (Figure 6 ). This dierence between bFGF and IGF-1 in modulating mAb 225-induced G1 arrest in our study is in agreement with the described role of bFGF as à competence' factor acting before the`restriction point', whereas IGF-1 as a`progression' factor acts after the cells traverse the`restriction point' in G1 phase. It is interesting to note that both bFGF and IGF-1 activated MAPK with similar kinetics; however, only . The concentrations were 20 mM for PD98059 and 10 mM for LY294002. Cell lysates were prepared and CDK2 activity was assayed by immunoprecipitation of the cell extracts with antibody against CDK2, followed by incubation of the immunoprecipitates with a reaction solution for the in vitro histone H1 assay as described in the text Figure 9 Dierential eects of PD98059 and LY294002 on blocking bFGF-and IGF-1-mediated prevention of DNA ladder induction by mAb 225. DiFi cells were cultured in medium containing 0.5% FBS with the indicated treatments for 24 h. The concentrations used for mAb 225, bFGF, IGF-1, PD98059 and LY294002 were the same as in Figure 8 . Both adherent and nonadherent cells were harvested for DNA extraction, followed by agarose gel analysis as described in the text bFGF eectively reversed the mAb 225-induced induction of p27 Kip1 and promoted cell traversal through the G1 phase.
In several cell lines we have studied so far, blockade of the EGF receptor with mAb 225 typically resulted in cell cycle arrest at G1 phase, accompanied by an increased expression of p27
Kip1 and a reduced level of CDK2 activity (Chou et al., 1999; Fan et al., 1997; Peng et al., 1996) . However, only in DiFi cells was the mAb 225-induced G1 arrest temporally followed by apoptosis. The exact mechanism by which mAb 225 induces apoptosis in DiFi cells has yet to be determined. DiFi cells could be auxotrophic, strictly depending on EGF receptor signaling for survival. EGF is well known as one of the most important mitogens for many epithelial cells (Ullrich and Schlessinger, 1990) , and recent studies from several laboratories have shown that, under certain circumstances, EGF can also act as a survival factor in suppressing apoptosis induced by various death signals (Caraglia et al., 1999; Gibson et al., 1999; Lan and Wong, 1999; Leu et al., 2000; McClellan et al., 1999; Payne et al., 1999) . In our study, we found that bFGF stimulated MAPK and inhibited the mAb 225-induced G1 arrest and apoptosis in a PD98059-sensitive but LY294002-insensitive manner. There was no detectable change in the level of phosphorylated Akt upon bFGF treatment. These results strongly indicate that the mechanism by which bFGF inhibits G1 arrest and apoptosis is mediated by the MEK/MAPK pathway in these cells. Although IGF-1 activated both the PI-3K/Akt and MEK/MAPK pathways, it failed to block mAb 225-induced G1 arrest and only delayed the onset of apoptosis in an LY294002-sensitive but PD98059-insensitive manner. Thus, our results suggest that the mechanism by which IGF-1 regulates mAb 225-induced apoptosis is mainly mediated by the PI-3K/ Akt pathway.
Our current study demonstrated a dierential modulation of mAb 225-induced G1 arrest and apoptosis by bFGF and IGF-1. A critical remaining question is whether there is a causal correlation between antibodyinduced G1 arrest and antibody-induced apoptosis. Why does mAb 225 induce apoptosis in DiFi cells but not in the other cell lines examined? Is the G1 arrest required for antibody-induced apoptosis or is it just an accompanying phenomenon? Exploration of answers to these questions may allow us to determine the de®nitive mechanism by which mAb 225 induces apoptosis in these cells.
Materials and methods
Reagents
The anti-EGF receptor mAb 225 has been described previously (Fan et al., 1993 (Fan et al., , 1994 Kawamoto et al., 1983; Sato et al., 1983 
Cell culture and proliferation assay
DiFi human colon adenocarcinoma cells were maintained in 1 : 1 (v/v) Dulbecco's modi®ed Eagle's medium (DMEM)/ Ham's F-12 mixture supplemented with 10% fetal bovine serum (FBS) in a 378C humidi®ed atmosphere containing 95% air and 5% CO 2 . Proliferation assays were performed in 12-well tissue plates with an initial cell density of 5610 4 cells/ well. DiFi cells were seeded in triplicate and exposed to mAb 225 with or without various growth factors in DMEM/Ham's F12 medium (1 : 1) with 0.5% FBS for 3 days. Cells were harvested by trypsinization and counted with a Coulter counter.
Hoechst staining
Cells (5610 5 ) were washed once with serum-free DMEM and then resuspended in 1 ml of serum-free DMEM containing 1 mg/ml Hoechst 33342 (Molecular Probes, Inc., Eugene, OR, USA) and 50 mg/ml propidium iodide (Roche Diagnostics Corp., Indianapolis, IN, USA) for 15 min at 378C. The cells were washed with 1 ml of serum-free DMEM three times and then resuspended in 400 ml of DMEM. The cell suspension was dropped onto glass slides and observed under ā uorescent microscope immediately.
Quantification of apoptosis
An apoptosis ELISA kit (Roche Diagnostics Corp.) was used to quantitatively measure cytoplasmic histone-associated DNA fragments (mononucleosomes and oligonucleosomes) as we previously reported (Liu et al., 2000) . This photometric enzyme immunoassay was performed exactly according to the manufacturer's instructions.
Caspase enzymatic activity assay
Caspase enzymatic activities were measured by using a colorimetric assay kit from Clontech Laboratories, Inc. (Palo Alto, CA, USA) as we previously reported (Liu et al., 2000) . The assay is based on spectrophotometric detection of the chromophore p-nitroanilide (pNA), which is cleaved from caspase-speci®c substrates by activated caspases (DEVDpNA by activated caspase-3, IETD-pNA by activated caspase-8, and LEHD-pNA by activated caspase-9).
Flow cytometric analysis
Cells grown in 100-mm culture dishes (2610 6 cells/dish) were harvested by trypsinization and ®xed with 70% ethanol. Cells (1 ± 2610 6 ) were stained for total DNA content with a solution containing 50 mg/ml propidium iodide and 100 mg/ml RNase I in PBS for 30 min at 378C. The cells were ®ltered through a nylon mesh (50-to 70-mm pore size) to remove cell clumps and then analysed for cell cycle distribution with a FACScan¯ow cytometer (Becton Dickinson, San JoseÂ , CA, USA).
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